Clinical perspective
malignant cardiac arrythmias
This study suggests a build-up of intracellular potassium levels over months that did not reflect changes in extracellular potassium in a simple manner, as the significant increase in p-K over weeks was attenuated after six months. If the level of potassium in the intracellular space affects the risk of malignant cardiac arrythmias, a greater effect of potassium-increasing treatment should be expected after months rather than weeks. This will be tested in the POTCAST trial.